吉西他滨
前药
体内
活性氧
胰腺癌
过氧化氢
胰腺导管腺癌
化学
毒性
化疗
药理学
不利影响
顺铂
体外
癌症研究
腺癌
癌症
医学
内科学
生物化学
生物
生物技术
有机化学
作者
Katsunori Matsushita,Takumi Okuda,S. Mori,Masamitsu Konno,Hidetoshi Eguchi,Ayumu Asai,Jun Koseki,Yoshifumi Iwagami,Daisaku Yamada,Hirofumi Akita,Tadafumi Asaoka,Takehiro Noda,Koichi Kawamoto,Kunihito Gotoh,Shogo Kobayashi,Yuuya Kasahara,Kunihiko Morihiro,Taroh Satoh,Yuichiro� Doki,Masaki Mori
出处
期刊:ChemMedChem
[Wiley]
日期:2019-06-17
卷期号:14 (15): 1384-1391
被引量:22
标识
DOI:10.1002/cmdc.201900324
摘要
Abstract The main concern in the use of anticancer chemotherapeutic drugs is host toxicity. Patients need to interrupt or change chemotherapy due to adverse effects. In this study, we aimed to decrease adverse events with gemcitabine (GEM) in the treatment of pancreatic ductal adenocarcinoma and focused on the difference of hydrogen peroxide levels in normal versus cancer cells. We designed and synthesized a novel boronate‐ester‐caged prodrug that is activated by the high H 2 O 2 concentrations found in cancer cells to release GEM. An H 2 O 2 ‐activatable GEM (A‐GEM) has higher selectivity for H 2 O 2 over other reactive oxygen species (ROS) and cytotoxic effects corresponding to the H 2 O 2 concentration in vitro. A xenograft model of immunodeficient mice indicated that the effect of A‐GEM was not inferior to that of GEM when administered in vivo. In particular, myelosuppression was significantly decreased following A‐GEM treatment compared with that following GEM treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI